Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Phys Chem B ; 127(47): 10201-10214, 2023 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-37972386

RESUMO

Lipids are known to play a vital role in the molecular organization of all cellular life. Molecular recognition is another fundamental biological process that is generally attributed to biological polymers, such as proteins and nucleic acids. However, there is evidence that aggregates of lipids and lipid-like molecules are also capable of selectively binding to or regulating the partitioning of other molecules. We previously demonstrated that a model two-phase octanol/water system can selectively partition Red 40 and Blue 1 dyes added to an aqueous phase, with the selectivity depending on the surfactant (e.g., cetyltrimethylammonium bromide) dissolved in the organic phase. Here, we elucidate the mechanism of molecular recognition in this system by using quantitative partitioning experiments and molecular dynamics (MD) simulations. Our results indicate that the selectivity for the red dye is thermodynamically favored at all surfactant concentrations, while selectivity for the blue dye is kinetically favored at high surfactant concentrations. The kinetic selectivity for the blue dye correlates with the presence of molecular aggregation at the oil-water interface. Coarse-grained MD simulations elucidate nanoscale supramolecular structures that can preferentially bind one small molecule rather than another at an interface, providing a selectively permeable barrier in the absence of proteins. The results suggest a new supramolecular mechanism for molecular recognition with potential applications in drug delivery, drug discovery, and biosensing.


Assuntos
Surfactantes Pulmonares , Tensoativos , Tensoativos/química , Água/química , Simulação de Dinâmica Molecular , Lipoproteínas , Corantes/química
2.
J Invertebr Pathol ; 201: 107995, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37748676

RESUMO

Picorna-like viruses of the order Picornavirales are a poorly defined group of positive-sense, single-stranded RNA viruses that include numerous pathogens known to infect plants, animals, and insects. A new picorna-like viral species was isolated from the wild lime psyllid (WLP), Leuronota fagarae, in the state of Florida, USA, and labelled: Leuronota fagarae picorna-like virus isolate FL (LfPLV-FL). The virus was found to have homology to a picorna-like virus identified in the Asian Citrus Psyllid (ACP), Diaphorina citri, collected in the state of Florida. Computational analysis of RNA extracts from WLP adult heads identified a 10,006-nucleotide sequence encoding a 2,942 amino acid polyprotein with similar functional domain structure to polyproteins of both Dicistroviridae and Iflaviridae. Sequence comparisons of nucleic acid and amino acid translations of the conserved RNA-dependent RNA polymerase, along with the entire N-terminal nonstructural coding region, provided insight into an evolutionary relationship of LfPLV-FL to insect-infecting iflaviruses. Viruses belonging to the family Iflaviridae encode a polyprotein of around 3000 amino acids in length that is processed post-translationally to produce components necessary for replication. The classification of a novel picorna-like virus in L. fagarae, with evolutionary characteristics similar to picorna-like viruses infecting Bactericera cockerelli and D. citri, provides an opportunity to examine virus host specificity, as well as identify critical components of the virus' genome required for successful transmission, infection, and replication. This bioinformatic classification allows for further insight into a novel virus species, and aids in the research of a closely related virus of the invasive psyllid, D. citri, a major pest of Floridian citriculture. The potential use of viral pathogens as expression vectors to manage the spread D. citri is an area that requires additional research; however, it may bring forth an effective control strategy to reduce the transmission of Candidatus Liberibacter asiaticus (CLas), the causative agent of Huanglongbing (HLB).


Assuntos
Citrus , Hemípteros , Rhizobiaceae , Vírus , Animais , Hemípteros/genética , Aminoácidos , Poliproteínas , Doenças das Plantas , Rhizobiaceae/genética
3.
Neonatal Netw ; 36(1): 32-39, 2017 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-28137351

RESUMO

The most common nonencapsulated solid renal tumor in the neonatal period is congenital mesoblastic nephroma. Mesoblastic nephroma is a solid lesion originating within or extending from the renal parenchyma. These tumors proliferate rapidly, typically within 3-6 months after birth. Mesoblastic nephromas are stratified by classification as either classical (benign) or atypical (malignant); masses composed of both benign and malignant cells are also reported. The hallmark clinical manifestation of mesoblastic nephroma is a palpable abdominal mass, which may be accompanied by hypertension, hypercalcemia, hematuria, and polyuria. Differentiating between benign and malignant renal tumors is essential to invoke a timely, evidence-based management and treatment plan. With appropriate surgical intervention in a timely manner, prognosis is excellent and mesoblastic nephroma is considered curable. We present a case involving a premature infant with congenital mesoblastic nephroma with discussion of embryology, pathophysiology, diagnostic, management, and prognostic implications for the neonate and family.


Assuntos
Hipertensão , Neoplasias Renais , Rim/patologia , Nefroma Mesoblástico , Gerenciamento Clínico , Resistência a Medicamentos , Humanos , Hipertensão/etiologia , Hipertensão/terapia , Recém-Nascido , Recém-Nascido Prematuro , Recém-Nascido de muito Baixo Peso , Neoplasias Renais/complicações , Neoplasias Renais/patologia , Neoplasias Renais/fisiopatologia , Masculino , Nefroma Mesoblástico/complicações , Nefroma Mesoblástico/patologia , Nefroma Mesoblástico/fisiopatologia , Planejamento de Assistência ao Paciente , Prognóstico , Resultado do Tratamento
4.
J Cell Physiol ; 232(3): 566-575, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27291835

RESUMO

The future of human mesenchymal stem cells (hMSCs) as a successful cell therapy relies on bioprocessing strategies to improve the scalability of these cells without compromising their therapeutic ability. The culture-expansion of hMSCs can be enhanced by supplementation with growth factors, particularly fibroblast growth factor 2 (FGF2). The biological activity of FGF2 is controlled through interactions with heparan sulfate (HS) that facilitates ligand-receptor complex formation. We previously reported on an FGF2-interacting HS variant (termed HS2) isolated from embryonic tissue by anionic exchange chromatography that increased the proliferation and potency of hMSCs. Here, we detail the isolation of an FGF2 affinity-purified HS variant (HS8) using a scalable platform technology previously employed to generate HS variants with increased affinity for BMP-2 or VEGF165 . This process used a peptide sequence derived from the heparin-binding domain of FGF2 as a substrate to affinity-isolate HS8 from a commercially available source of porcine mucosal HS. Our data show that HS8 binds to FGF2 with higher affinity than to FGF1, FGF7, BMP2, PDGF-BB, or VEGF165 . Also, HS8 protects FGF2 from thermal destabilization and increases FGF signaling and hMSC proliferation through FGF receptor 1. Long-term supplementation of cultures with HS8 increased both hMSC numbers and their colony-forming efficiency without adversely affecting the expression of hMSC-related cell surface antigens. This strategy further exemplifies the utility of affinity-purifying HS variants against particular ligands important to the stem cell microenvironment and advocates for their addition as adjuvants for the culture-expansion of hMSCs destined for cellular therapy. J. Cell. Physiol. 232: 566-575, 2017. © 2016 Wiley Periodicals, Inc.


Assuntos
Fator 2 de Crescimento de Fibroblastos/metabolismo , Heparitina Sulfato/metabolismo , Células-Tronco Mesenquimais/citologia , Células-Tronco Mesenquimais/metabolismo , Sequência de Aminoácidos , Anticoagulantes/farmacologia , Proliferação de Células , Cromatografia de Afinidade , Dissacarídeos/análise , Fator Xa/metabolismo , Fator 2 de Crescimento de Fibroblastos/química , Heparitina Sulfato/isolamento & purificação , Humanos , Células-Tronco Mesenquimais/efeitos dos fármacos , Peptídeos/química , Peptídeos/metabolismo , Estabilidade Proteica/efeitos dos fármacos , Receptor Tipo 1 de Fator de Crescimento de Fibroblastos/metabolismo , Transdução de Sinais/efeitos dos fármacos
5.
Biomaterials ; 35(25): 6776-86, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24854095

RESUMO

The therapeutic use of VEGF165 to stimulate blood vessel formation for the treatment of peripheral arterial disease or cardiovascular-related disease has met with limited success. Here we describe an affinity-isolated heparan sulfate glycotherapeutic (HS7(+ve)) that binds to, and enhances the bioactivity of, VEGF165. Application of HS7(+ve) complexed with VEGF165 results in enhanced VEGF165-VEGFR2 interaction, prolonged downstream pErk1/2 signalling, and increased cell proliferation and tube formation in HUVECs, compared with VEGF165 alone. The pro-angiogenic potential of HS7(+ve) was further assessed in vivo using the chick embryo chorioallantoic membrane (CAM) assay. Exogenous dosing with HS7(+ve) alone significantly enhanced the formation of new blood vessels with potencies comparable to VEGF165. These results demonstrate the potential for vascular therapy of glycotherapeutic agents targeted at augmenting the bioactivity of VEGF165.


Assuntos
Heparitina Sulfato/farmacologia , Engenharia de Proteínas/métodos , Doenças Vasculares/tratamento farmacológico , Fator A de Crescimento do Endotélio Vascular/metabolismo , Indutores da Angiogênese/química , Indutores da Angiogênese/farmacologia , Técnicas Biossensoriais , Vasos Sanguíneos/efeitos dos fármacos , Vasos Sanguíneos/metabolismo , Proliferação de Células/efeitos dos fármacos , Heparitina Sulfato/química , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/metabolismo , Humanos , Ligação Proteica , Transdução de Sinais
6.
EMBO Mol Med ; 4(9): 866-81, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22887873

RESUMO

Intestinal pathogens use the host's excessive inflammatory cytokine response, designed to eliminate dangerous bacteria, to disrupt epithelial gut wall integrity and promote their tissue invasion. We sought to develop a non-antibiotic-based approach to prevent this injury. Molecular docking studies suggested that glycosylated dendrimers block the TLR4-MD-2-LPS complex, and a 13.6 kDa polyamidoamine (PAMAM) dendrimer glucosamine (DG) reduced the induction of human monocyte interleukin (IL)-6 by Gram-negative bacteria. In a rabbit model of shigellosis, PAMAM-DG prevented epithelial gut wall damage and intestinal villous destruction, reduced local IL-6 and IL-8 expression, and minimized bacterial invasion. Computational modelling studies identified a 3.3 kDa polypropyletherimine (PETIM)-DG as the smallest likely bioactive molecule. In human monocytes, high purity PETIM-DG potently inhibited Shigella Lipid A-induced IL-6 expression. In rabbits, PETIM-DG prevented Shigella-induced epithelial gut wall damage, reduced local IL-6 and IL-8 expression, and minimized bacterial invasion. There was no change in ß-defensin, IL-10, interferon-ß, transforming growth factor-ß, CD3 or FoxP3 expression. Small and orally delivered DG could be useful for preventing gut wall tissue damage in a wide spectrum of infectious diarrhoeal diseases.


Assuntos
Dendrímeros/administração & dosagem , Disenteria Bacilar/tratamento farmacológico , Fármacos Gastrointestinais/administração & dosagem , Trato Gastrointestinal/efeitos dos fármacos , Glucosamina/análogos & derivados , Interleucina-6/antagonistas & inibidores , Interleucina-8/antagonistas & inibidores , Administração Oral , Animais , Translocação Bacteriana/efeitos dos fármacos , Diarreia/tratamento farmacológico , Diarreia/patologia , Modelos Animais de Doenças , Disenteria Bacilar/patologia , Trato Gastrointestinal/patologia , Glucosamina/administração & dosagem , Fatores Imunológicos/administração & dosagem , Coelhos , Shigella/patogenicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA